Rituxan
Roche’s Phase 3 Pemphix trial smashes primary endpoint for pemphigus vulgaris
October 14, 2019Research and Development, Sales and Marketing MabThera, Rituxan, Roche, pharma
Roche has revealed new Phase 3 data demonstrating that its MabThera/Rituxan (rituximab) therapy Pemphix met its primary endpoint in the …
Roche secures US paediatric approval for Rituxan in two rare forms of vasculitis
September 30, 2019Sales and Marketing MabThera, Rituxan, Roche, pharma, vasculitis
Roche has revealed that Rituxan (rituximab), also known as MabThera, has been awarded US approval from the FDA in combination …
FDA approves Pfizer’s biosimilar version of Genentech’s Rituxan
July 24, 2019Research and Development FDA, Pfizer, Rituxan, Ruxience, biosimilars, pharma
Pfizer has seen Ruxience, its biosimilar version of Genentech’s Rituxan (rituximab), approved by the FDA in the treatment of non-Hodgkin …
FDA approves first Rituxan biosimilar courtesy of Teva and Celltrion
November 29, 2018Sales and Marketing FDA, Genentech, Rituxan, Roche, Teva, Truxima, biosimilars, celltrion
The FDA has announced the first US approval of a biosimilar version of Genentech’s Rituxan (rituximab), awarding marketing approval to …
Celltrion’s Rituxan biosimilar gets unanimous backing from FDA committee
October 11, 2018Sales and Marketing FDA, Oncologic Drugs Advisory Committee, Rituxan, Roche, Truxima
FDA approval looks to be in reach for Celltrion, as an advisory committee for the US regulator voted unanimously to …
Roche and AbbVie’s leukaemia combo smashes Phase 3 endpoint
September 19, 2017Manufacturing and Production, Research and Development AbbVie, Rituxan, Roche, Venclexta, Venclyxto, leukaemia, pharma, pharmaceutical
Venclexta/Venclyxto (venetoclax), Roche and AbbVie’s oral B-cell lymphoma-2 (BCL-2) inhibitor, successfully met its primary endpoint in Phase 3 trials, providing …
FDA accepts license application for Novartis’ rituximab biosimilar
September 12, 2017Manufacturing and Production, Sales and Marketing Novartis, Rituxan, Sandoz, biosimilar, rituximab
Sandoz, Novartis’ generics and biosimilars division, has revealed that the FDA has accepted its Biologics License Application (BLA) for a …
Novartis receives European biosimilar approval for Roche blockbuster
June 19, 2017Sales and Marketing Novartis, Rituxan, Rixathon, Roche
Sandoz, a division within Novartis, has received European Commission approval for its biosimilar version of Roche’s Rituxan (also known as …
Strong growth for Roche in latest results
July 25, 2013Sales and Marketing Alexion, Q2, Rituxan, Roche
Roche has seen strong sales growth in the past six months as it lines up new products to replace its …
New Roche leukaemia drug beats rival
July 24, 2013Research and Development, Sales and Marketing Rituxan, Roche, leukaemia, obinutuzumab
Roche’s next generation leukaemia drug obinutuzumab has beaten the firm’s ageing blood cancer medicine Rituxan in a late-stage trial. The …
NICE recommends MabThera for non-Hodgkin’s lymphoma
December 6, 2010Sales and Marketing MabThera, NICE, Rituxan, Roche, non-Hodgkin’s lymphoma, rituximab
NICE has given a preliminary green-light to Roche’s MabThera for use as a maintenance therapy for non-Hodgkin’s lymphoma. The Institute’s …
Biogen set to axe 650 jobs and focus on neurology
November 4, 2010Research and Development, Sales and Marketing Biogen, Rituxan, job cuts, pharma jobs
Biogen Idec is set to cut hundreds of jobs and refocus its R&D in an effort to cut costs by …
MabThera gains maintenance therapy licence
October 29, 2010Medical Communications, Sales and Marketing MabThera, Rituxan, Roche, lymphoma
Roche’s MabThera has been approved as a maintenance therapy for follicular lymphoma, a common type of blood cancer. Maintenance treatment …
Rituxan gains approval for most common leukaemia
February 19, 2010Sales and Marketing FDA, MabThera, Rituxan, blood cancer
Roche’s blockbuster cancer treatment MabThera/Rituxan has been approved by the FDA for the treatment of adult leukaemia. The drug earned …
Latest content
